Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.
about
Gender differences in ankylosing spondylitis-associated cumulative healthcare utilization: a population-based cohort studyHealth care costs associated with ankylosing spondylitis in Turkey: an analysis from nationwide real-world data.Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.Challenges comparing functional limitations in rheumatoid arthritis and ankylosing spondylitisAdalimumab in ankylosing spondylitis: an evidence-based review of its place in therapy.Cost-Effectiveness Evaluation of Etoricoxib versus Celecoxib and Nonselective NSAIDs in the Treatment of Ankylosing Spondylitis in Norway.Large differences in cost of illness and wellbeing between patients with fibromyalgia, chronic low back pain, or ankylosing spondylitisMarkov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitisCost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in GermanyThe Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data.Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis.Direct and indirect costs associated with ankylosing spondylitis and related disease activity scores in Turkey.A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis.Economic considerations of the treatment of ankylosing spondylitis.Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis.Safety and clinical responses in ankylosing spondylitis after three months of etanercept therapy.Health care utilization in patients with spondyloarthropathies.Cost-of-illness and quality of life in patients with ankylosing spondylitis at a tertiary hospital in Korea.Review of the costs of illness of ankylosing spondylitis and methodologic notes.Health-related quality of life in patients with ankylosing spondylitis: a comprehensive review.The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis.Welfare costs in patients with rheumatoid arthritis and their partners compared with matched controls: a register-based study.The economic burden of the ankylosing spondylitis in the Czech Republic: comparison between 2005 and 2008.Prevalence and associated risk factors for work disability in Egyptian patients with ankylosing spondylitis from one center.The relationship between depressive symptoms, illness perceptions and quality of life in ankylosing spondylitis in comparison to rheumatoid arthritis.Indirect and direct costs of treating patients with ankylosing spondylitis in the Brazilian public health system.Development of a prognostic score for work disability in Romanian patients with ankylosing spondylitis.Cost-effectiveness Analysis of Golimumab in the Treatment of Non-Radiographic Axial Spondyloarthritis in Scotland.Cost–effectiveness of tumor necrosis factor-α antagonists in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
P2860
Q24634228-76798969-7F2A-497D-98B0-11D6DA617432Q30603471-7D376781-33C6-451C-A634-3F25E6068582Q33275865-91A96BD1-EBEE-4FEE-AE46-E06CBA38238BQ34192955-0845638F-6C24-42DF-8105-4939DA703388Q34449888-809C6304-4BB7-44AE-9FCA-D47A6062FB00Q35098611-58F1B623-33F4-4EAE-BBC2-502BBDFC7B8CQ35555306-64F5109E-73F0-40FC-B3D9-CBE21D7F52C7Q35636708-55839F15-1A46-49BE-AE7F-219CC07FDB63Q35637894-03977E3B-0545-4745-8B01-696E56496C39Q35694344-FB0FC83A-3EFD-48E8-908D-394E15B2D249Q35953401-14C0D09A-1970-46DC-9578-9936508AD879Q35967949-0CDA58AA-15B9-4159-B280-A8240BFAE83DQ36157440-56210129-49A2-4114-BF80-73192B6BCB54Q36611047-690D9FD2-CC3D-4C80-8AA0-ED363719D6CEQ36731613-AC3B5265-788A-45EA-9215-0B434CB7C132Q36773202-2785D4F6-65DC-4162-8236-97B82F35B5E2Q36966051-EE657D61-6633-4EB8-80E2-D35EF1FEA257Q37294500-6FE0E290-4637-4B79-9792-D66BF08F17DEQ37583028-322611F3-A603-4351-A9A0-8F0BD7C93AAEQ37609388-8D29CD23-0AD4-477A-A944-E78C6F908FA2Q38246381-EA862281-F63E-46A4-AE67-A3E0B12673A6Q38314640-F8FE60B8-827A-4ABA-9344-D78F8ED0FF45Q39248083-283B6ED8-8A08-44B1-8942-540A9E937503Q39486298-BCF3ED5B-76B6-4A7F-8A00-647B6D2356AFQ44077285-6A36D210-20B0-44F0-85DA-AC47C2816609Q45910248-E91EC0CB-64AD-469F-B2D7-C870F00D9FFDQ47777720-63B195E6-ACB5-49FE-8C10-91E76BEE01ABQ51820032-287ABEFB-DA63-49FB-8492-E591D3522A92Q54994756-4EAB47DB-8FCB-4ED7-8CBC-B477C7CD67B0Q57658712-62755BA0-DC5D-4B19-BC99-D60193BE881A
P2860
Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Direct costs of ankylosing spo ...... mong three European countries.
@ast
Direct costs of ankylosing spo ...... mong three European countries.
@en
type
label
Direct costs of ankylosing spo ...... mong three European countries.
@ast
Direct costs of ankylosing spo ...... mong three European countries.
@en
prefLabel
Direct costs of ankylosing spo ...... mong three European countries.
@ast
Direct costs of ankylosing spo ...... mong three European countries.
@en
P2093
P2860
P356
P1476
Direct costs of ankylosing spo ...... mong three European countries.
@en
P2093
A Spoorenberg
F Guillemin
H Mielants
H Schouten
H van der Tempel
M Dougados
M Rutten-van Mölken
P2860
P304
P356
10.1136/ARD.62.8.732
P407
P577
2003-08-01T00:00:00Z